Skip to main content
main-content

The independent medical news service

07-05-2019 | Oncology | News | Article

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

29-03-2019 | Oncology | News | Article

Flu vaccine not contraindicated for checkpoint inhibitor-treated cancer patients

A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.

30-10-2018 | Oncology | News | Article

Continued benefits of immunotherapy shown in advanced melanoma

An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

18-10-2018 | Melanoma | News | Article

Neoadjuvant checkpoint blockade investigated in high-risk melanoma

In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.

14-09-2018 | Oncology | Main feed | News

EMA supports encorafenib plus binimetinib combination

Read more here

07-09-2018 | Melanoma | News | Article

FDG-PET predicts metastatic melanoma outcomes better than CT imaging

Using 18F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.

Image Credits